DPT antibodies target dermatopontin, a multifunctional extracellular matrix (ECM) protein encoded by the *DPT* gene. Dermatopontin plays a critical role in ECM organization, cell-matrix interactions, and tissue homeostasis. It binds to collagen, fibronectin, and decorin, facilitating collagen fibrillogenesis and promoting ECM stability. Additionally, it modulates TGF-β signaling, influencing cell adhesion, proliferation, and wound healing. Dysregulation of dermatopontin has been linked to fibrotic disorders, skin diseases, and cancer progression, where altered ECM remodeling is a hallmark.
DPT antibodies are essential tools for studying dermatopontin's expression, localization, and functional roles in both physiological and pathological contexts. They are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to assess protein levels in tissues or cell cultures. In research, these antibodies help elucidate mechanisms underlying fibrosis, tumor microenvironment modulation, and connective tissue disorders. Commercially available DPT antibodies are typically raised in hosts like rabbits or mice, with validation for specificity across human, mouse, and rat samples. Their applications extend to diagnostic exploration, particularly in diseases characterized by ECM abnormalities, making them valuable for both basic research and potential therapeutic development.